<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686749</url>
  </required_header>
  <id_info>
    <org_study_id>Bio-858981</org_study_id>
    <nct_id>NCT02686749</nct_id>
  </id_info>
  <brief_title>Catheter Ablation vs. Medical Therapy in Congested Hearts With AF</brief_title>
  <acronym>CATCH-AF</acronym>
  <official_title>Catheter Ablation vs. Medical Therapy in Congested Hearts With AF (CATCH-AF in Patients With Impaired LV Function): An Early Ablation Strategy Study Impact on Health Care Utilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oussama Wazni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, unblinded, clinical trial. The objective is to
      determine if catheter-based atrial fibrillation (AF) ablation is superior to medical
      treatment in patients with impaired left ventricular (LV) function who have been diagnosed
      with symptomatic AF within the past 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the trial is to compare two different approved treatments for recently
      diagnosed AF: anti-arrhythmic medications and AF ablation. The study will be conducted to
      determine if one treatment is more effective than the other for patients with AF and heart
      failure. About 220 subjects with newly diagnosed AF from hospitals in the United States will
      take part in this study. Subjects will be randomized in a 1:1 fashion to either AF catheter
      ablation or anti-arrhythmic medication for treatment of AF. Both therapies are considered
      Standard of Care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study randomizes subjects to already FDA approved treatment modalities. Approved anti-arrhythmic medications or AF ablation. There are no investigational drug or devices used.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First hospitalization for heart failure, recurrence of AF or Direct Current cardioversion</measure>
    <time_frame>12 months</time_frame>
    <description>Time measured in days to first hospitalization for heart failure, recurrence of AF or Direct Current cardioversion after the treatment period (first 3 months post enrollment or post procedure during which repeat ablation can be performed and titration of AADs can be performed).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of cardiovascular hospitalization</measure>
    <time_frame>15 months</time_frame>
    <description>total number of cardiovascular hospitalization measured by hospitalization admissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence if AF lasting longer than 30 seconds</measure>
    <time_frame>15 months</time_frame>
    <description>time measured in days to recurrence of AF lasting longer than 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance walked in a 6-mile walk test</measure>
    <time_frame>3 months through 15 months</time_frame>
    <description>change in distance walked in 6 mile walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Rand 36-Item Health Survey</measure>
    <time_frame>3 months through 15 months</time_frame>
    <description>change in the Rand 36-Item Health Survey reflective of change in patient's quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ejection Fraction (EF)</measure>
    <time_frame>baseline through15 months</time_frame>
    <description>Change in Ejection Fraction heart failure measurement (percentage)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Left Ventricular Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AF catheter Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDA approved anti arrhythmic drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which &quot;disconnects&quot; the pathway of the AF.</description>
    <arm_group_label>AF catheter Ablation</arm_group_label>
    <other_name>Pulmonary Vein Isolation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDA approved anti arrhythmic drug</intervention_name>
    <description>Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines</description>
    <arm_group_label>FDA approved anti arrhythmic drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must be 18 years of age or older

          -  Provide signed written Informed Consent

          -  symptomatic AF documented by EKG or heart rhythm monitoring within 12 months

          -  patients should be on optimal medical therapy for heart failure for 3 months prior to
             randomization. Adjustments to medications within this 3 month period are permitted.

          -  chronically impaired LV function defined as EF between 20%-45% within last 3 months

          -  all patients should be on an optimal therapy for impaired LV function

          -  ability to complete 6 minute walk test

          -  eligible for catheter ablation and anti-arrhythmic drugs

        Exclusion Criteria:

          -  women of childbearing potential unless post- menopausal or surgically sterile

          -  patients hospitalized for heart failure within the 3 months prior to randomization

          -  reversible causes of AF such as pericarditis, thyroid disorders, acute alcohol
             intoxication, recent major surgical procedures or trauma

          -  recent reversible LV impairment that may be attributed to AF with rapid ventricular
             response and may improve with introduction of rate control

          -  valvular heart disease requiring surgical intervention

          -  Coronary Artery Disease (CAD) requiring surgical or percutaneous intervention

          -  early post-operative AF (within 3 months of surgery)

          -  previous MAZE or left atrial instrumentation (including ablation and left atrial
             appendage exclusion)

          -  history of Atrioventricular Node (AVN) ablation

          -  hypertrophic cardiomyopathy

          -  prolonged QT interval

          -  liver failure

          -  renal failure requiring dialysis

          -  social factors that would preclude follow up or make compliance difficult- history of
             drug, alcohol or substance abuse

          -  contraindications to the use of AADs and/or anticoagulation therapy

          -  Currently enrolled in, or discontinued within the last 30 days from a clinical trial
             involving an investigational product or non-approved use of a drug or device or
             concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study.

          -  severe pulmonary disease

          -  documented intra-atrial thrombus, tumor, or structural abnormality which precludes
             catheter introduction

          -  unwilling to comply with protocol requirements or deemed by the investigator to be
             unfit for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oussama Wazni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison D Kirkholder, BSN</last_name>
    <phone>216-445-8070</phone>
    <email>kirkhoa@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edmond M Cronin, MD</last_name>
      <phone>860-972-1506</phone>
      <email>edmond.cronin@hhchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Deborah M Katten, RN</last_name>
      <phone>860-972-1537</phone>
      <email>Deborah.katten@hhchealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Akron General</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Schweikert, MD</last_name>
      <phone>330-344-4377</phone>
      <email>Robert.schweikert@akrongeneral.org</email>
    </contact>
    <contact_backup>
      <last_name>Tonya Frederick, MSN</last_name>
      <phone>330-344-1430</phone>
      <email>Tonya.frederick@akrongeneral.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oussama Wazni, MD</last_name>
      <phone>216-444-6697</phone>
      <email>waznio@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Panko, RN</last_name>
      <phone>216-444-6478</phone>
      <email>pankom@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Houmsse, MD</last_name>
      <phone>614-293-4967</phone>
      <email>Mahmoud.Houmsse@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Smith, RN</last_name>
      <phone>614-685-4624</phone>
      <email>Jennifer.Smith6@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Supple, MD</last_name>
      <phone>215-615-3811</phone>
      <email>Gregory.supple@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Gnap, RN</last_name>
      <phone>215 349 8446</phone>
      <email>Mary.gnap@uphs.upenn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nassir Marrouche, MD</last_name>
      <phone>801-581-2572</phone>
      <email>Nassir.marrouche@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katt Mackin</last_name>
      <phone>801-581-7287</phone>
      <email>Katt.mackin@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982 Apr 29;306(17):1018-22.</citation>
    <PMID>7062992</PMID>
  </reference>
  <reference>
    <citation>Van den Berg MP, Tuinenburg AE, Crijns HJ, Van Gelder IC, Gosselink AT, Lie KI. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997 Apr;77(4):309-13. Review.</citation>
    <PMID>9155607</PMID>
  </reference>
  <reference>
    <citation>Chen MS, Marrouche NF, Khaykin Y, Gillinov AM, Wazni O, Martin DO, Rossillo A, Verma A, Cummings J, Erciyes D, Saad E, Bhargava M, Bash D, Schweikert R, Burkhardt D, Williams-Andrews M, Perez-Lugones A, Abdul-Karim A, Saliba W, Natale A. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol. 2004 Mar 17;43(6):1004-9.</citation>
    <PMID>15028358</PMID>
  </reference>
  <reference>
    <citation>Wyse DG. Some recent randomized clinical trials in the management of atrial fibrillation. J Interv Card Electrophysiol. 2003 Oct;9(2):223-8. Review.</citation>
    <PMID>14574035</PMID>
  </reference>
  <reference>
    <citation>Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004 Mar 30;109(12):1509-13. Epub 2004 Mar 8.</citation>
    <PMID>15007003</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Oussama Wazni</investigator_full_name>
    <investigator_title>Professor of Medicine, Co-Director of AF and VT Centers</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

